You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 15, 2024

Heron Theraps Inc Company Profile


✉ Email this page to a colleague

« Back to Dashboard


What is the competitive landscape for HERON THERAPS INC, and what generic alternatives to HERON THERAPS INC drugs are available?

HERON THERAPS INC has four approved drugs.

There are thirty-two US patents protecting HERON THERAPS INC drugs.

There are ninety-eight patent family members on HERON THERAPS INC drugs in twenty-one countries and seven supplementary protection certificates in four countries.

Summary for Heron Theraps Inc
International Patents:98
US Patents:32
Tradenames:4
Ingredients:3
NDAs:4

Drugs and US Patents for Heron Theraps Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Heron Theraps Inc APONVIE aprepitant EMULSION;INTRAVENOUS 216457-001 Sep 16, 2022 RX Yes Yes 10,500,208 ⤷  Subscribe Y ⤷  Subscribe
Heron Theraps Inc APONVIE aprepitant EMULSION;INTRAVENOUS 216457-001 Sep 16, 2022 RX Yes Yes 9,974,793 ⤷  Subscribe Y ⤷  Subscribe
Heron Theraps Inc APONVIE aprepitant EMULSION;INTRAVENOUS 216457-001 Sep 16, 2022 RX Yes Yes 11,878,074 ⤷  Subscribe ⤷  Subscribe
Heron Theraps Inc ZYNRELEF KIT bupivacaine; meloxicam SOLUTION, EXTENDED RELEASE;PERIARTICULAR 211988-002 May 12, 2021 RX Yes Yes 10,898,575 ⤷  Subscribe Y ⤷  Subscribe
Heron Theraps Inc APONVIE aprepitant EMULSION;INTRAVENOUS 216457-001 Sep 16, 2022 RX Yes Yes 11,744,800 ⤷  Subscribe Y ⤷  Subscribe
Heron Theraps Inc ZYNRELEF KIT bupivacaine; meloxicam SOLUTION, EXTENDED RELEASE;PERIARTICULAR 211988-001 May 12, 2021 DISCN Yes No 11,844,837 ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Heron Theraps Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Heron Theraps Inc SUSTOL granisetron INJECTABLE;SUBCUTANEOUS 022445-001 Aug 9, 2016 9,913,910 ⤷  Subscribe
Heron Theraps Inc SUSTOL granisetron INJECTABLE;SUBCUTANEOUS 022445-001 Aug 9, 2016 10,357,570 ⤷  Subscribe
Heron Theraps Inc SUSTOL granisetron INJECTABLE;SUBCUTANEOUS 022445-001 Aug 9, 2016 8,715,710 ⤷  Subscribe
Heron Theraps Inc SUSTOL granisetron INJECTABLE;SUBCUTANEOUS 022445-001 Aug 9, 2016 8,252,304 ⤷  Subscribe
Heron Theraps Inc SUSTOL granisetron INJECTABLE;SUBCUTANEOUS 022445-001 Aug 9, 2016 8,252,305 ⤷  Subscribe
Heron Theraps Inc SUSTOL granisetron INJECTABLE;SUBCUTANEOUS 022445-001 Aug 9, 2016 6,790,458 ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for Heron Theraps Inc Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0734381 04C0010 France ⤷  Subscribe PRODUCT NAME: APREPITANT; REGISTRATION NO/DATE: EU/1/03/262/001 20031111
0748320 SPC/GB08/021 United Kingdom ⤷  Subscribe PRODUCT NAME: FOSAPREPITANT AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR THE BIS(N-METHYL-D-GLUCAMINE)SALT; REGISTERED: UK EU/1/07/437/001 20080111; UK EU/1/07/437/002 20080111
0748320 08C0019 France ⤷  Subscribe PRODUCT NAME: FOSAPREPITANT DIMEGLUMINE; REGISTRATION NO/DATE: EU/1/07/437/001 20080111
0734381 SPC/GB04/011 United Kingdom ⤷  Subscribe PRODUCT NAME: APREPITANT, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/03/262/001 20031113; UK EU/1/03/262/002 20031113; UK EU/1/03/262/003 20031113; UK EU/1/03/262/004 20031113; UK EU/1/03/262/005 20031113; UK EU/1/03/262/006 20031113
0734381 PA2004002,C0734381 Lithuania ⤷  Subscribe PRODUCT NAME: 5-(((2R,3S)-2-((1R)-1-(3,5-BIS(TRIFLUORMETIL)FENIL)ETOKSI)-3-(4-FLUORFENIL)-4-MORFOLINIL)METIL)-1,2-DIHIDRO-3H-1,2,4-TRIAZOL-3-ONAS (APREPITANTAS); REGISTRATION NO/DATE: EU/1/03/262/001, 2003 11 11, EU/1/03/262/002, 2003 11 11, EU/1/03/262/003, 2003 11 11, EU/1/03/262/004, 2003 11 11, EU/1/03/262/005, 2003 11 11, EU/1/03/262/006 20031111
0734381 PA2004002 Lithuania ⤷  Subscribe PRODCUT NAME: 5-[[(2R,3S)-2-[(1R)-1-[3,5-BIS(TRIFLUORMETIL)FENIL]ETOKSI]-3-(4-FLUORFENIL)-4-MORFOLINIL]METIL]-1,2-DIHIDRO-3H-1,2,4-TRIAZOL-3-ONAS (APREPITANTAS); REGISTRATION NO./DATE: EU/1/03/262/001-006/20031111
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.